Legend Capital's Co-founded Company Innostellar Biotherapeutics: IRD Gene Therapy Product was Approved for Clinical Trial in China

HONG KONG, Apr 24, 2022 - (ACN Newswire) - Shanghai Langsheng Biotechnology Co., Ltd., a subsidiary of Legend Capital's co-founded company Innostellar Biotherapeutics, announced that the clinical trial

Related Keywords

China ,Fenghua ,Zhejiang ,Chinese ,Innovent Biologics ,Kostenloser Wertpapierhandel ,Exegenesis Bio ,Innostellar Biotherapeutics ,Recbio Technology ,Kawin Technology ,Lynk Pharmaceuticals ,National Medical Products Administration Of China ,National Clinical Research Center ,Shanghai Langsheng Biotechnology Co Ltd ,Legend Capital ,Drug Evaluation ,National Medical Products Administration ,Eye Diseases ,Harbour Biomed ,Suzhou Ribo Life Science ,Legend ,Capital ,Wounded ,Company ,Nnostellar ,Iotherapeutics ,Gene ,Therapy ,Product ,Approved ,Linical ,Trial ,